First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88)
antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody
expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88,
expressed on cancer cells.
This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD)
and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before
the dose expansion portion (1B) of the study is initiated. The dose escalation portion of
this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01
antibody to be evaluated in the cohort expansion portion (1B).